Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes
Authors' conclusion
Dapagliflozin and exenatide monotherapy cause sustained improvements in BCF and insulin sensitivity. Combination therapy with dapagliflozin plus exenatide markedly augmented both BCF and insulin sensitivity above that with either agent alone.
Study context
- Population
- Patients with T2D
- Participants
- 90 patients
- Comparison
- Dapagliflozin vs exenatide vs dapagliflozin/exenatide vs placebo
- Placebon = 15reference
- Dapagliflozinn = 25
- Exenatiden = 25
- Dapagliflozin/exenatiden = 25
- Outcome
- β-cell function (BCF) during 180-min oral glucose tolerance test (OGTT)
Methodological detailsplacebo-controlled, acute single-dose study and 1- and 4-month therapy
- Placebo-controlled
- Acute single-dose study and 1- and 4-month therapy
Main finding
As reported in the abstract
BCF index · acute study
Placebo
0.40
SE 0.04
Dapagliflozin
0.65
SE 0.10
Exenatide
1.17
SE 0.22
Dapagliflozin/exenatide
1.69
SE 0.12
Dapagliflozin vs Placebo: P < 0.05 · Exenatide vs Placebo: P < 0.001 vs. placebo · Dapagliflozin/exenatide vs Placebo: P < 0.001 vs. placebo
Further findings
Mean
| Outcome | Placebo | Dapagliflozin | Exenatide | Dapagliflozin/exenatide |
|---|---|---|---|---|
| Corrected Matsuda index (cMI) · acute study | 1.63 (SE 0.36) | 2.29 (SE 0.33) | 2.03 (SE 0.12) | 2.36 (SE 0.14) |
- Corrected Matsuda index (cMI) — cMI higher in all active groups than placebo
- P < 0.05
BCF · 1 and 4 months
- BCF rose further in dapagliflozin and exenatide but did not increase further in dapagliflozin/exenatide
cMI · 1 and 4 months
- cMI remained similarly elevated in exenatide and increased further in dapagliflozin and dapagliflozin/exenatide
- P < 0.001
Insulin secretion · acute study
- Dapagliflozin similar to placebo; higher in exenatide and dapagliflozin/exenatide vs both
- P < 0.001
Insulin secretion · 1 and 4 months
- Higher in exenatide and dapagliflozin/exenatide than dapagliflozin
- P < 0.01
Original publication
Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes. Diabetes Care. Published 8 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →